{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T05:56:20Z","timestamp":1674366980308},"reference-count":36,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2023]]},"DOI":"10.1620\/tjem.2022.j104","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T22:12:04Z","timestamp":1669846324000},"page":"113-119","source":"Crossref","is-referenced-by-count":0,"title":["Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report"],"prefix":"10.1620","volume":"259","author":[{"given":"Haruna","family":"Furukawa","sequence":"first","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nomura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shori","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Takeda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Oka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Shirota","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Kodera","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Okitsu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Pathology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Asatsuma-Okumura, T., Ito, T. &amp; Handa, H. (2019)  Molecular mechanisms of cereblon-based drugs.  <i>Pharmacol. Ther<\/i>., 202, 132-139.","DOI":"10.1016\/j.pharmthera.2019.06.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Balaian, E., Schuster, C., Schonefeldt, C., Germing, U., Haase, D., Tuve, S., Ordemann, R., Ehninger, G., Bornhauser, M., Oelschlaegel, U., Mohr, B., von Bonin, M., Platzbecker, U. &amp; Wermke, M. (2016)  Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.  <i>Ann. Hematol<\/i>., 95, 1805-1810.","DOI":"10.1007\/s00277-016-2775-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Balduini, C.L., Salvaneschi, L., Klersy, C., Noris, P., Mazzucco, M., Rizzuto, F., Giorgiani, G., Perotti, C., Stroppa, P., Pumpo, M.D., Nobili, B. &amp; Locatelli, F. (2001)  Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation.  <i>Leukemia<\/i>, 15, 1885-1891.","DOI":"10.1038\/sj.leu.2402307"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Brauer, D.L., Edelman, B., Rapoport, A.P., Hess, J.R. &amp; Akpek, G. (2012)  Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease.  <i>Transfusion<\/i>, 52, 2432-2435.","DOI":"10.1111\/j.1537-2995.2012.03608.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Darabi, K., Kantamnei, S. &amp; Wiernik, P.H. (2006)  Lenalidomide-induced warm autoimmune hemolytic anemia.  <i>J. Clin. Oncol<\/i>., 24, e59.","DOI":"10.1200\/JCO.2006.08.4053"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Dasanu, C.A. &amp; Alexandrescu, D.T. (2009)  A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.  <i>Eur. J. Haematol<\/i>., 82, 231-234.","DOI":"10.1111\/j.1600-0609.2008.01176.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Fattizzo, B., Ireland, R., Dunlop, A., Yallop, D., Kassam, S., Large, J., Gandhi, S., Muus, P., Manogaran, C., Sanchez, K., Consonni, D., Barcellini, W., Mufti, G.J., Marsh, J.C.W. &amp; Kulasekararaj, A.G. (2021)  Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia.  <i>Leukemia<\/i>, 35, 3223-3231.","DOI":"10.1038\/s41375-021-01190-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Forehand Iii, W., Ajebo, G., Toscano, M., Jillella, A. &amp; Dainer, P. (2020)  Lenalidomide-associated immune thrombocytopenia: a case report and review of the literature.  <i>Case Rep. Hematol<\/i>., 2020, 8825618.","DOI":"10.1155\/2020\/8825618"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Galustian, C., Meyer, B., Labarthe, M.C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J.B. &amp; Dalgleish, A.G. (2009)  The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.  <i>Cancer Immunol. Immunother<\/i>., 58, 1033-1045.","DOI":"10.1007\/s00262-008-0620-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gandhi, A.K., Kang, J., Havens, C.G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M.F., Thakurta, A., Klippel, A., Handa, H., Daniel, T.O., Schafer, P.H. &amp; Chopra, R. (2014)  Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).  <i>Br. J. Haematol<\/i>., 164, 811-821.","DOI":"10.1111\/bjh.12708"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Giagounidis, A.A., Germing, U., Strupp, C., Hildebrandt, B., Heinsch, M. &amp; Aul, C. (2005)  Prognosis of patients with del(5q)  MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.  <i>Ann. Hematol<\/i>., 84, 569-571.","DOI":"10.1007\/s00277-005-1054-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Gilli, S.C., de Souza Medina, S., de Castro, V., Fernandes, L.G. &amp; Saad, S.T. (2012)  Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes. <i>Leuk. Res<\/i>., 36, 554-559.","DOI":"10.1016\/j.leukres.2011.10.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Herold, C.I., Gasparetto, C. &amp; Arepally, G.M. (2011)  Lenalidomide-associated ITP. <i>Case Rep. Hematol.<\/i>, 2011, 638020.","DOI":"10.1155\/2011\/638020"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Ioannou, N., Jain, K. &amp; Ramsay, A.G. (2021)  Immunomodulatory drugs for the treatment of B cell malignancies.  <i>Int. J. Mol. Sci<\/i>., 22, 8572.","DOI":"10.3390\/ijms22168572"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Jachiet, V., Moulis, G., Hadjadj, J., Seguier, J., Laribi, K., Schleinitz, N., Vey, N., Sacre, K., Godeau, B., Beyne-Rauzy, O., Bouvet, R., Broner, J., Brun, N., Comont, T., Gaudin, C.,  et al. (2021)  Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.  <i>Haematologica<\/i>, 106, 1414-1422.","DOI":"10.3324\/haematol.2020.272559"},{"key":"16","doi-asserted-by":"crossref","unstructured":"J\u00e4dersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Gohring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellstrom-Lindberg, E. &amp; Mufti, G.J. (2011)  TP53 mutations in low-risk myelodysplastic syndromes with del(5q)  predict disease progression.  <i>J. Clin. Oncol<\/i>., 29, 1971-1979.","DOI":"10.1200\/JCO.2010.31.8576"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Kelton, J.G., Murphy, W.G., Lucarelli, A., Garvey-Williams, J., Santos, A., Meyer, R. &amp; Powers, P. (1989)  A prospective comparison of four techniques for measuring platelet-associated IgG.  <i>Br. J. Haematol<\/i>., 71, 97-105.","DOI":"10.1111\/j.1365-2141.1989.tb06281.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Kr\u00f6nke, J., Fink, E.C., Hollenbach, P.W., MacBeth, K.J., Hurst, S.N., Udeshi, N.D., Chamberlain, P.P., Mani, D.R., Man, H.W., Gandhi, A.K., Svinkina, T., Schneider, R.K., McConkey, M., Jaras, M., Griffiths, E.,  et al. (2015)  Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS.  <i>Nature<\/i>, 523, 183-188.","DOI":"10.1038\/nature14610"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Kr\u00f6nke, J., Udeshi, N.D., Narla, A., Grauman, P., Hurst, S.N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S.L.,  et al. (2014)  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.  <i>Science<\/i>, 343, 301-305.","DOI":"10.1126\/science.1244851"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kulasekararaj, A.G., Smith, A.E., Mian, S.A., Mohamedali, A.M., Krishnamurthy, P., Lea, N.C., Gaken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., Pomplun, S., Marsh, J.C. &amp; Mufti, G.J. (2013)  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.  <i>Br. J. Haematol<\/i>., 160, 660-672.","DOI":"10.1111\/bjh.12203"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Li, J., Zhou, J., Guo, W., Wang, X., Zhao, Y. &amp; Bai, O. (2021)  Efficacy and safety of lenalidomide monotherapy for relapsed\/refractory diffuse large B cell lymphoma: systematic review and meta-analysis.  <i>Front. Oncol<\/i>., 11, 756728.","DOI":"10.3389\/fonc.2021.756728"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Lindner, S. &amp; Kr\u00f6nke, J.(2016)  The molecular mechanism of thalidomide analogs in hematologic malignancies.  <i>J. Mol. Med. <\/i>(<i>Berl.<\/i>), 94, 1327-1334.","DOI":"10.1007\/s00109-016-1450-z"},{"key":"23","doi-asserted-by":"crossref","unstructured":"List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J.,  et al. (2006)  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.  <i>N. Engl. J. Med<\/i>., 355, 1456-1465.","DOI":"10.1056\/NEJMoa061292"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Liu, J., Ye, J., Zou, X., Xu, Z., Feng, Y., Zou, X., Chen, Z., Li, Y. &amp; Cang, Y. (2014)  CRL4A(CRBN) E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis.  <i>Nat. Commun<\/i>., 5, 3924.","DOI":"10.1038\/ncomms4924"},{"key":"25","unstructured":"Meguri, Y., Kanbayashi, Y., Yamamoto, A., Masunari, T., Sezaki, N. &amp; Kiguchi, T. (2018)  Development of unexpected severe thrombocytopenia just after initiating lenalidomide: possible involvement of an immunologic mechanism.  <i>Int. J. Myeloma<\/i>, 8, 1-3."},{"key":"26","doi-asserted-by":"crossref","unstructured":"Merz, M., Dechow, T., Scheytt, M., Schmidt, C., Hackanson, B. &amp; Knop, S. (2020)  The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.  <i>Ann. Hematol<\/i>., 99, 1709-1725.","DOI":"10.1007\/s00277-020-04023-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Miltiadous, O., Hou, M. &amp; Bussel, J.B. (2020)  Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.  <i>Blood<\/i>, 135, 472-490.","DOI":"10.1182\/blood.2019003599"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Montefusco, V., Galli, M., Spina, F., Stefanoni, P., Mussetti, A., Perrone, G., De Philippis, C., Dalto, S., Maura, F., Bonini, C., Rezzonico, F., Pennisi, M., Roncari, L., Soldarini, M., Dodero, A.,  et al. (2014)  Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.  <i>Leuk. Lymphoma<\/i>, 55, 2032-2037.","DOI":"10.3109\/10428194.2014.914203"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Neuber, B., Dai, J., Waraich, W.A., Awwad, M.H.S., Engelhardt, M., Schmitt, M., Medenhoff, S., Witzens-Harig, M., Ho, A.D., Goldschmidt, H. &amp; Hundemer, M. (2017)  Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(-)  T-cells.  <i>Oncotarget<\/i>, 8, 98200-98214.","DOI":"10.18632\/oncotarget.21516"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Pompa, A., Guidotti, F., Gregorini, A.I., Goldaniga, M.C., Rossi, F.G., Baldini, L.B. &amp; Cortelezzi, A. (2016)  Four cases of Lenalidomide-associated immune thrombocytopenia.  <i>Blood<\/i>, 128, 4927.","DOI":"10.1182\/blood.V128.22.4927.4927"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Saburi, M., Ogata, M., Soga, Y., Satou, T., Itani, K., Kohno, K. &amp; Nakayama, T. (2021)  Association between platelet-associated immunoglobulin G levels and response to corticosteroid therapy in patients with newly diagnosed immune thrombocytopenia.  <i>Acta Haematol<\/i>., 144, 528-533.","DOI":"10.1159\/000511698"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G.J., Kulasekararaj, A., Gohring, G., Giagounidis, A., Selleslag, D., Muus, P., Sanz, G., Mittelman, M., Bowen, D., Porwit, A., Fu, T.,  et al. (2014)  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).  <i>Haematologica<\/i>, 99, 1041-1049.","DOI":"10.3324\/haematol.2013.098103"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Slichter, S.J., Davis, K., Enright, H., Braine, H., Gernsheimer, T., Kao, K.J., Kickler, T., Lee, E., McFarland, J., McCullough, J., Rodey, G., Schiffer, C.A. &amp; Woodson, R. (2005)  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.  <i>Blood<\/i>, 105, 4106-4114.","DOI":"10.1182\/blood-2003-08-2724"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Smith, J.N.P., Kanwar, V.S. &amp; MacNamara, K.C. (2016)  Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia.  <i>Front. Immunol<\/i>., 7, 330.","DOI":"10.3389\/fimmu.2016.00330"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Strati, P., Takahashi, K., Peterson, C.B., Keating, M.J., Thompson, P.A., Daver, N.G., Jain, N., Burger, J.A., Estrov, Z., O\u2019Brien, S.M., Kantarjian, H.M., Wierda, W.G., Futreal, P.A. &amp; Ferrajoli, A. (2019)  Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.  <i>Blood Adv<\/i>., 3, 1533-1539.","DOI":"10.1182\/bloodadvances.2019031336"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Ximeri, M., Galanopoulos, A., Klaus, M., Parcharidou, A., Giannikou, K., Psyllaki, M., Symeonidis, A., Pappa, V., Kartasis, Z., Liapi, D., Hatzimichael, E., Kokoris, S., Korkolopoulou, P., Sambani, C., Pontikoglou, C.,  et al. (2010)  Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.  <i>Haematologica<\/i>, 95, 406-414.","DOI":"10.3324\/haematol.2009.010876"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/259\/2\/259_2022.J104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:47:23Z","timestamp":1674276443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/259\/2\/259_2022.J104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2022.j104","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"2022.J104"}}